Today, a brief rundown of news involving Regeneron Pharmaceuticals, IGM Biosciences and Catalio Capital, as well as updates from Roche, Hikma Pharmaceuticals and several others that you may have missed.

今天，简要概述一下涉及再生元制药、IGM生物科学和Catalio资本的新闻，以及罗氏、Hikma制药等其他几家公司的更新，你可能错过了这些消息。

The Food and Drug Administration on Wednesday

食品和药物管理局周三

approved

已批准

Regeneron Pharmaceuticals

再生元制药公司

bispecific antibody

双特异性抗体

linvoseltamab

林沃塞他单抗

for relapsed or refractory multiple myeloma. The clearance was based on tumor response rates in clinical testing and is conditional on Regeneron obtaining confirmatory evidence of the drug’s benefit in further study. Regeneron previously tried to secure an FDA OK of the drug last year, but had its application .

用于治疗复发性或难治性多发性骨髓瘤。该药物的批准是基于临床试验中的肿瘤反应率，并且有条件要求再生元公司在进一步研究中获取证实药物益处的确凿证据。再生元公司去年曾尝试获得FDA对该药物的批准，但其申请未获通过。

rejected

拒绝

due to issues with a third-party manufacturer. Linvoseltamab, which Regeneron will sell as

由于第三方制造商的问题。Linvoseltamab，再生元将作为销售商品。

Lynozyfic

林诺齐菲克

, is one of two bispecific antibodies the company hopes will boost its oncology business. The other,

，是该公司希望将促进其肿瘤学业务的两种双特异性抗体之一。另一种，

odronextamab

奥德罗单抗

, is under regulatory review for lymphoma, with a decision expected by July 30. —

，正在接受淋巴瘤的监管审查，预计将于 7 月 30 日做出决定。—

Ned Pagliarulo

内德·帕利亚鲁洛

Concentra Biosciences

康赛特拉生物科学

is buying another struggling biotechnology company, this time agreeing to pay roughly $1.25 per share to acquire

正在收购另一家陷入困境的生物技术公司，这次同意支付每股约1.25美元进行收购。

IGM Biosciences.

IGM生物科学公司。

The entity controlled by Tang Capital Partners

由唐资本合伙公司控制的实体

announced Tuesday

周二宣布

that IGM’s shareholders would also receive a contingent value right equal to 80% of the proceeds of a deal involving IGM’s intellectual property and experimental drugs, as well as all net cash in excess of $82 million at closing. IGM's board unanimously approved the merger agreement, and the deal is expected to close in August.

IGM 的股东还将获得一笔或有价值权，相当于涉及 IGM 知识产权和实验药物的交易收益的 80%，以及在交割时超过 8200 万美元的所有净现金。IGM 董事会一致批准了该合并协议，预计交易将在八月完成。

Last month, Concentra brokered a similar agreement with .

上个月，Concentra 与某公司达成了类似的协议。

Elevation Oncology

高地肿瘤学

, and previously acquired companies Jounce Therapeutics and Kronos Bio. —

，以及之前收购的公司Jounce Therapeutics和Kronos Bio。—

Gwendolyn Wu

关朵琳·吴

Venture capital firm

风险投资公司

Catalio Capital Management

加泰罗资本管理公司

has brought in more than $400 million for its latest healthcare investment fund,

为其最新的医疗保健投资基金筹集了超过4亿美元，

according to a Tuesday announcement

根据周二的公告

. The fund is its fourth since launching in 2020. Recently, Catalio invested in the AI drug discovery company

这是自2020年成立以来的第四只基金。最近，Catalio投资了人工智能药物发现公司

Superluminal Medicines

超光速医药

and antibody-drug conjugate developer Alentis Therapeutics. Catalio will continue investing in 'deals with prospects for near-term liquidity,' as well as 'prospects for long-term growth,' said

以及抗体药物偶联物开发商Alentis Therapeutics。Catalio将继续投资于“具有短期流动性前景”和“长期增长前景”的交易。

Diamantis Xylas

迪亚曼蒂斯·希拉斯

, Catalio's head of research. —

，卡塔利奥研究主管。——

Gwendolyn Wu

吴瑰琳

With biotech markets still unsettled, several drugmakers this week turned to royalty and debt deals to obtain new funding.

由于生物技术市场仍然不稳定，本周几家制药公司转向了特许权和债务交易以获得新的资金。

BridgeBio Pharma

桥生物制药

secured $300 million to support launching its new drug Attruby with

筹集了3亿美元以支持其新药Attruby的推出。

an agreement

协议

that sells some of the company’s royalties on sales of the medicine in Europe, where it’s marketed by Bayer. Meanwhile,

出售了该公司在欧洲的药品销售版税，该药品在欧洲由拜耳公司销售。与此同时，

Dyne Therapeutics

Dyne治疗学公司

will receive up to $275 million in

将获得高达2.75亿美元的

debt financing

债务融资

via a deal with

通过与...的协议

Hercules Capital

赫拉克勒斯资本

, and

，以及

Apellis

Apellis

will trade

将进行交易

Sobi

索比

up to 90% of ex-U.S. royalties on sales of its drug Aspaveli for as much as $300 million. —

高达其药物Aspaveli销售额的90%的非美国地区特许权使用费，金额至多为3亿美元。

Ned Pagliarulo

内德·帕利亚鲁洛

Roche

罗氏

said two of its top executives

表示其两名最高层管理人员

will be retiring from the company

将从公司退休

, leaving vacancies on its corporate executive committee.

，其企业执行委员会留下空缺。

Johannes Clevers

约翰内斯·克莱弗斯

, head of Roche pharma research and early development since 2022, will step down in August from his current role but remain as leader of the company’s Institute of Human Biology until a successor can be found.

自 2022 年以来担任罗氏制药研究和早期开发主管的。。。将在 8 月卸任目前的职位，但在找到继任者之前，他将继续担任公司人类生物学研究所的负责人。

Barbara Schädler

巴巴拉·沙德勒

, head of group communications who’s been employed by Roche since 2019, will retire at the end of the year. Roche said it will announce successors “in due course.” —

自2019年以来受雇于罗氏的集团传播主管将于今年年底退休。罗氏表示，将“适时”宣布继任者。

Jonathan Gardner

乔纳森·加德纳

Generic drugmaker

通用药物制造商

Hikma

智慧

plans on spending $1 billion to boost its U.S. manufacturing and research and development capacity by 2030, the

计划到2030年投入10亿美元，以提升其在美国的制造、研发能力，

company said Saturday

公司周六表示

. Hikma said the expansion will “increase the company's US-based capacity to produce large volumes of high-quality and affordable medicines,” which currently stands at 12 billion doses a year. The U.K.-based company joins

.Hikma表示，此次扩张将“增加公司在美国的产能，以生产大量高质量且价格合理的药物”，目前其年产量为120亿剂。这家总部位于英国的公司加入了

Johnson & Johnson

强生公司

,

，

Eli Lilly

礼来公司

,

，

Merck & Co.

默克公司

,

，

Novartis

诺华

,

，

Roche

罗氏

and

和

Gilead Sciences

吉利德科学公司

in pledging to build up U.S.-based manufacturing as President Donald Trump has threatened tariffs on drugs produced overseas. Hikma has facilities in Ohio and New Jersey. —

承诺加强美国本土制造，因为总统唐纳德·特朗普威胁要对海外生产的药品征收关税。Hikma在俄亥俄州和新泽西州设有工厂。

Jonathan Gardner

乔纳森·加德纳